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The capsid protein L2 plays major roles in both papillomavirus assembly and the infectious process.
While L1 forms the majority of the capsid and can self-assemble into empty virus-like particles (VLPs),
L2 is a minor capsid component and lacks the capacity to form VLPs. However, L2 co-assembles with L1
into VLPs, enhancing their assembly. L2 also facilitates encapsidation of the ∼8 kbp circular and
nucleosome-bound viral genome during assembly of the non-enveloped T¼7d virions in the nucleus
of terminally differentiated epithelial cells, although, like L1, L2 is not detectably expressed in infected
basal cells. With respect to infection, L2 is not required for particles to bind to and enter cells. However
L2 must be cleaved by furin for endosome escape. L2 then travels with the viral genome to the nucleus,
wherein it accumulates at ND-10 domains. Here, we provide an overview of the biology of L2.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPV) are the etiologic agent of 5% of
all lethal cases of cancer worldwide, and even benign infections can
cause considerable morbidity for patients and expense to the
healthcare system. While the oncogenic HPV genotypes are the
best studied, many fundamental observations have ﬁrst been made
with animal papillomaviruses (zur Hausen, 2002). Productive infec-
tion by papillomaviruses occurs in many vertebrates and exhibits a
strict host tropism and a requirement for epithelial differentiation.
Animal papillomaviruses, notably cottontail rabbit papillomavirus
(CRPV), bovine papillomavirus (BPV), rabbit oral papillomavirus
(ROPV), have been invaluable models for virologic, and especially
vaccine studies. These animal papillomavirus models remain impor-
tant because of many technical challenges associated with the
oncogenic HPV genotypes; HPV cannot be grown in cultured cancer
cell lines, obtaining virions of oncogenic HPV genotypes from
clinical lesions is not feasible, infection is not lytic (and thus fails
to produce a readily measurable phenotype), and ﬁnally infection of
animals with HPV does not produce lesions due to strict host
tropism. Over the years, many of these hurdles have been circum-
vented through the use of organotypic raft culture to produce nativell rights reserved.
e Johns Hopkins University,
31, USA. Fax: +443 287 4295.virions (Conway et al., 2009b; Meyers et al., 1997), or the codon
optimization of the capsid genes enabling robust L1 and L2
expression for the formation of pseudovirions (PsV) carrying a
reporter construct (Buck et al., 2004) that can be used to challenge
mice or even primates (Roberts et al., 2007, 2011). While much of
the seminal work was performed with animal papillomavirus,
fortunately there appears to be a strong conservation of both the
domains and functions of L2 across the Papillomaviridae.
At present, there are over a hundred known HPV genotypes
that are categorized into ﬁve genera (alpha, beta, gamma, mu and
nu) based upon their genomic sequence (Bernard et al., 2010; de
Villiers et al., 2004). They can also be subdivided based on their
tropism for either cutaneous or mucosal epithelium respectively,
as well as their association with cancer or solely benign lesions.
Cutaneous HPV types are typically “low-risk” as their infections are
either asymptomatic or result in self-limited and benign tumors,
as seen for the gamma types such as HPV1 and HPV2 that cause
warts. The beta types, notably HPV5 and HPV8, are typically
asymptomatic in healthy individuals, but have been associated
with non-melanoma squamous cell carcinoma (SCC) in patients
with epidermodysplasia verruciformis (a hereditary condition
resulting from germline mutations in EVER1 or EVER2), or upon
immune suppression due to HIV co-infection or drug treatment
upon solid organ transplantation. Most mucosal HPV types are also
benign, such as HPV6 or HPV11, but a dozen or so “high risk” or
“oncogenic” genotypes are carcinogenic. While the majority of
oncogenic HPV infections are self-limited and subject to immune
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increased risk for the development of cervical, other anogenital
and/or oropharanygeal cancers. HPV types 16 and 18 account for
50% and 20% of all cervical cancer cases respectively. Other high/
intermediate risk types such as HPV31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68 constitute the remaining 30% HPV-associated malig-
nancies and are associated with a slower onset of dysplasia (de
Martel et al., 2012). Importantly, HPV16 is even more predominant
(∼90%) in other anogenital and oropharyngeal malignancies (Buck
and Trus, 2012; zur Hausen, 2002). Given its disproportionate
impact on human health, most studies of L2 biology are concen-
trated on HPV16.
The circular and double-stranded papillomavirus genome
encodes six ‘early’ proteins (E1, E2, E4, E5, E6, and E7) and two
‘late’ proteins (L1 and L2), subdivided based on their spatial–
temporal expression pattern during the virus life cycle. The ‘early’
proteins can be further subdivided into two regulatory genes
involved in replication and transcription (E1 and E2), three
oncogenes (E5, E6 and E7), and E4 which contributes to virion
production and actually exhibits an expression pattern closer to
the late proteins. The late proteins L1 and L2 are structural
components of the viral capsid (Doorbar et al., 2012). Expression
of L1 and L2 is not detected in infected basal epithelial cells, but
they are both detected in the nuclei of the terminally differen-
tiated cells in the uppermost layers of the squamous epithelium,
appearing ﬁrst even later (i.e. higher in the epithelium) than E4.
When produced in a variety of recombinant expression systems, L1
can self-assemble, to form empty virus-like particles (VLPs) that
are the basis of the licensed HPV vaccines (Kirnbauer et al., 1992).
L2 does not form VLPs but can be incorporated when co-expressed
with L1. In this review, we will be focusing on the biology of the
minor capsid protein, L2, which plays a key role both during virion
assembly and the infectious process.Fig. 1. Diagram of known neutralizing epitope regions and protein interaction domains
Diagram was adapted and updated from Karanam et al. (2009). See Table 1 for a full lisThe L2 protein
L2 is just under 500 amino acids in length, which corresponds to
an estimated molecular mass of approximately 55 KDa. However,
L2 typically exhibits an apparent molecular weight of 64–78 kDa by
SDS-PAGE analysis (Doorbar and Gallimore, 1987; Jin et al., 1989;
Komly et al., 1986; Rippe and Meinke, 1989). The reason for this
phenomenon is unclear as there are no known post-translational
modiﬁcations of L2 (with the exception of modiﬁcation by SUMO of
lysine 35 of HPV16 L2 (Marusic et al., 2010), and a similar size is
observed for L2 produced in bacteria. Rose et al. (1990) reported that
L2 in native HPV11 virions exhibited a doublet, but the size of L2 was
not impacted by glycosylase treatment, suggesting that glycosylation
was not a factor, and the lower molecular weight form might instead
represent proteolytic cleavage . L2 has several key functional roles and
numerous interacting partners (Table 2). The main domain sequences
used by L2 have been mapped through deletion and/or mutagenesis
studies (Fig. 1). Much of our discussion and analysis here will be based
on HPV16 L2's primary sequence and these mapped domains because
very little information exists on its higher order structure.Structural biology: L2 in the context of the papillomavirus capsid
The basic architecture of the papillomavirus virion is a non-
enveloped T¼7d icosahedral capsid with a diameter of 55–60 nm
(Fig. 2A). Each virion contains 360 L1 proteins. L1 ﬁrst stably
assembles into star-shaped units of ﬁve called capsomers (some-
times termed ‘pentamers’) that have a central donut-like cavity,
and the capsid is formed by the association of 72 such capsomeres
via interlocking arms and disulﬁde bridging. The capsid also
contains an ill-deﬁned number of L2 proteins; although up to 72
L2 proteins have been estimated in a single capsid (1:5 L2 to L1of HPV16 L2. Regions that were discovered using other PV L2 types are indicated.
t of neutralizing antibodies.
Fig. 2. Arrangement of L1 and L2 in HPV16 capsids. 3D reconstructions derived by comparing cryo-electron micrograph images of HPV16 capsids made of L1+L2 versus L1
only (Buck et al., 2008; Buck and Trus, 2012) (A). Interior of L1+L2 capsid without DNA and histones (B). Arrangement of L2 density (red) areas superimposed on the interior
view of L1 only capsid (in blue) (C). Clustal analysis of L1-binding domain of L2 showing several conserved proline (PxxP) motifs (D). Clustal analysis was performed with the
UCSF Chimera package. Images were reproduced with permission of Benes Trus (NIH), Christopher Buck (NIH) and American Society for Microbiology.
J.W. Wang, R.B.S. Roden / Virology 445 (2013) 175–186 177proteins ratio) (Buck et al., 2008; Buck and Trus, 2012). Smaller
amounts have also been described in preparations of native virions
puriﬁed from bovine and human warts, e.g. 8% (Rippe and Meinke,
1989), 3% (Trus et al., 1997) or 2–5% (Favre et al., 1975). These lower
percentages may reﬂect a naturally lower occupancy, proteolytic
degradation and/or the presence of empty particles in the pre-
parations fromwarts, as the latter have been associated with lower
fractions of L2.
Studies by Finnen et al. on HPV11 revealed that there is an
L1-binding site at the carboxy-terminus of L2 (residues 396–439 in
HPV11 L2) and Okun et al. mapped an analogous site mapped in
BPV1 L2, but also observed another L1 interaction domain
between 91 and 246 (Finnen et al., 2003; Okun et al., 2001). The
C-terminal L1-binding region of L2 is characterized by several
proline residues (PxxP) and similar PxxP motifs have been asso-
ciated with protein–protein interactions in other systems. Homo-
logous PxxP motifs were observed in a similar region of the
C-termini of other L2 thus suggesting that this is a well conserved
L1-binding site on PV L2 (Fig. 2D). As binding of L2 to L1 was not
affected signiﬁcantly under conditions of high salt, weak deter-
gents, urea and pH, it appears that the main mode of L1:L2
interaction is hydrophobic in nature. However, the L1 residues
mediating the interaction with L2 in the capsid remain undeﬁned,
although some speculative modeling has been done based on the
available X-ray crystallographic structure of L1 VLPs which suggest
that L2 might interact with L1 via the N-terminus (Buck et al.,
2008; Lowe et al., 2008). Also, puriﬁed L1 VLP and L2 are unable to
form complexes in vitro without co-expression and this suggeststhat their interaction must occur prior to capsid assembly or at the
capsomer level rather than insertion of L2 into a formed L1 VLP
(Finnen et al., 2003; Okun et al., 2001).
The amino terminus of L2 contains two highly conserved
cysteine residues (C22 and C28) (see Fig. 5) across all PV types
which form an intra-molecular disulﬁde hairpin loop rather than
bridging with L1. Studies using HPV16 PsV showed that the point
mutation of either or both cysteine residues resulted non-
infectious virions but did not affect virus capsid assembly. How-
ever, this effect was not observed for BPV1 PsV (Campos and
Ozbun, 2009; Gambhira et al., 2009). Interestingly, using PV made
from organotypic raft cultures, Conway et al. found that mutating
these cysteine residues improved infectivity compared to wild-
type. The authors suggested that this remarkable difference could
possibly be attributed to differences in virion preparation produ-
cing subtle differences in capsid structure between PV made in cell
culture versus differentiating epithelial tissue. In addition, it was
suggested that these cysteine residues potentially play a key role
in late stage capsid stabilization by modulating the accessibility of
L2 on the surface of raft-derived virions (Conway et al., 2009a).
Antibody binding studies suggest that L2 is predominantly
hidden below the surface of native virions although its conﬁgura-
tion remains unknown. A detailed study using antisera to over-
lapping peptides covering the entire HPV16 L2 sequence suggested
that several regions (residues 32–81, 212–231, 272–291 and 347–
381) are accessible on the surface of HPV16 L1/L2 VLPs (Heino
et al., 1995). However, in another study using several monoclonal
antibodies raised against BPV1 L2 protein, only the region 61–123
J.W. Wang, R.B.S. Roden / Virology 445 (2013) 175–186178was actually exposed on the surface of BPV1 virions (Liu et al.,
1997). Likewise, other studies mapping neutralizing epitopes in
HPV16 L2 (see below in immunology section) suggest that only the
ﬁrst amino-terminal ∼120 amino acids are available for binding
(Kawana et al., 1998; Rubio et al., 2011; Yang et al., 2003a).
However, care must be taken in interpreting the studies with
neutralizing antibodies as the HPV virions undergo conformational
changes during the infectious process that appear to alter access of
L2 to the capsid surface. Further, these conformational shifts might
also be triggered upon binding of mature virions to the surface of
microtiter plates for ELISA-type studies. In conclusion, it is still
controversial which regions of L2 are actually exposed on the
capsid surface of fully mature virions in solution. For example, the
epitope in HPV16 L2 17–36 recognized by the RG-1 monoclonal
antibody is accessible on virions bound to ELISA plates, but not
mature virions in solution (Day et al., 2008). Rather, it becomes
revealed after binding to the extracellular matrix and furin
cleavage of L2 (Kines et al., 2009). However, other studies indicate
that L2 residues 13–31 and 100–120 are constitutively exposed on
the capsid surface (Richards et al., 2006; Yang et al., 2003a). Thus
much of L2 is buried below the capsid surface of mature virions,
but certain amino-terminal regions of L2 can be exposed on the
cell surface during the early events of viral infection (Buck and
Trus, 2012) (see section on viral host cell entry for details).
Unfortunately, no X-ray crystallographic structures are avail-
able for capsids containing L2. Several efforts at high resolution
three dimensional image reconstruction of cryo-electron micro-
graphs of native BPV1, HPV1 or CRPV virions, HPV1 or HPV16 VLPs
have attempted to visualize L2 in the capsid (Baker et al., 1987;
Belnap et al., 1996; Buck et al., 2008; Buck and Trus, 2012;
Hagensee et al., 1994; Trus et al., 1997). However, most studies
failed to visualize L2, possibly reﬂecting inadequate incorporation
into the capsid, degradation, disorder or lack of symmetry. A study
by Trus et al. detected some protein density at the center of the
capsomers at the 5-fold axes of symmetry (pentameric capsomers)
of native BPV1 virions, but not the hexameric capsomers, that
might be L2. However protein density associated with L2 could not
be deﬁnitely assigned and the ratio of L1:L2 in BPV1 virions used
in this study was ∼30:1 (Trus et al., 1997). However, in a more
recent study comparing the structure of HPV16 L1 only versus L1
+L2 particles in which the ratio of L1:L2 was driven close to 5:1,
protein density was observed at the base of the axial lumen of all
capsomers that was absent in L1 only particles (Fig. 2A–C). This is
consistent with the notion that much of L2 is buried below the
capsid surface, although little of L2 was visualized as the density
corresponded with only a small fraction (∼12 kDa) of its mass
(Buck et al., 2008; Buck and Trus, 2012).
L2 facilitates genome encapsidation
L1 and L2 were found to have DNA-binding activity in vitro
(Li et al., 1997; Mallon et al., 1987; Schafer et al., 2002), ﬁrst
suggesting that both capsid proteins may aid in viral genome
encapsidation by directly binding to DNA without sequence
speciﬁcity. These putative DNA-binding regions are conserved
short sequences of positively charged basic residues found at the
carboxy-terminus of L1 and in both the amino and carboxy termini
of L2. The DNA-binding region of L1 of HPV33 is necessary for DNA
encapsidation (Schafer et al., 2002). Likewise, L2 (Roden et al.,
1996; Zhao et al., 1998) has also been reported to be required for
efﬁcient DNA/viral genome encapsidation for BPV1, although the
effect may be less pronounced for HPV16, HPV31 (Buck et al.,
2004; Holmgren et al., 2005) and HPV33 (Unckell et al., 1997).
Deletion of either the N-terminal or the C-terminal DNA-binding
domain from BPV1 L2 had no impact upon BPV1 genome encapsi-
dation but rendered the virions non-infectious (Roden et al.,2001). However, the impact of deletion of the DNA-binding
domains at both termini was not tested because these domains
can also function as nuclear localization signals (NLS) (Bordeaux
et al., 2006; Doorbar et al., 2012; Fay et al., 2004; Klucevsek et al.,
2006; Zhou et al., 1994), complicating interpretation of these data.
Taken together, there is no evidence for sequence-speciﬁc DNA
interaction with either capsid protein, but in vitro there is a non-
speciﬁc ionic interaction between the negatively charged DNA and
these short sequences rich in positively charged amino acids
(although there signiﬁcance for virion assembly is unclear). Further,
L2 can bring components of the PV virion to speciﬁc locations in the
nucleus deﬁned as ND-10 and Day et al. hypothesized that L2 co-
localizes/organizes L1, E2 and viral genome to facilitate encapsida-
tion of the histone-bound genome and virion assembly (Day et al.,
1998; Florin et al., 2006), although E2 is not required for packaging
reporter constructs into PsV (Buck et al., 2004).
L2 and host cell entry
There are currently two competing models of papillomavirus
infection events prior to cell entry (Kines et al., 2009; Surviladze
et al., 2012). However both agree that L2 starts predominantly buried
within the capsid and its exposure requires a conformational change
induced by capsid binding to heparan sulfate proteoglycans that is
anchored in the extracellular matrix in vitro or the basement
membrane in vivo, or possibly in solution. This binding induces
changes in the conformation of the capsid such that the very amino
terminus of L2 extrudes to the capsid surface and becomes suscep-
tible to cleavage by the pro-convertase enzyme furin in the extra-
cellular milieu, thus removing one of the putative NLS (Day and
Schiller, 2009; Johnson et al., 2009; Kines et al., 2009; Richards et al.,
2006; Selinka et al., 2003). Analysis of the N-terminus of all PV types
reveals that the consensus furin cleavage motif site (R-X-K/R-R)
(Fig. 3B) is conserved at around amino acids 9–12 (Richards et al.,
2006). Numerous PV types exhibit reduced infectivity upon exposure
to furin inhibitors both in vitro and in vivo, and furin deﬁcient cells
are not infected unless complemented with the a furin expression
vector or extracellular addition of furin. Point mutation of the furin
cleavage site also rendered virions non-infectious (Richards et al.,
2006). Thus cleavage of L2 by furin is required for infection and
results in further capsid conformational changes. The virus is subse-
quently internalized via an undeﬁned secondary receptor found on
the host cell basal keratinocyte (Fig. 3A). Importantly, furin cleavage
also exposes a broadly neutralizing epitope (amino acid region 17–
36) which was ﬁrst characterized using the RG-1 monoclonal anti-
body (Gambhira et al., 2007b).
Richards et al. showed L2 with point mutation of L2 preventing
furin cleavage did not affect PsV production. These mutant PsV had
typical levels of L2 and were able to encapsidate the reporter
genome normally. These mutant capsids were also able to bind to
the cell surface, enter the cell, trafﬁc through the endosomes and
uncoat normally. However, the mutant L2 and reporter genome
were unable to leave the endosome even after 24 h post-infection
while wildtype L2 and reporter genome accumulated in the
nucleus. Endosomal retention was also observed in infection
studies with wildtype PsV incubated with a furin inhibitor. These
ﬁndings suggest that furin cleavage of L2 is important for the exit
of the L2/genome complex from the endosomal compartment (Day
and Schiller, 2009; Richards et al., 2006).
There is no clear difference in the initial internalization of
L1 VLPs and L1/L2 VLPs visualized by ﬂuorescence microscopy. This
suggests that it is either L1 that binds to the secondary unknown
entry receptor or these particles are able to internalize but via
subtly distinct pathways that are not currently discernable by
ﬂuorescence microcopy. Assuming the latter, it has been proposed
that furin cleavage exposes on the surface of the capsid a previously
Fig. 3. A model depiction of the early events of PV infection in the cervical epithelium in vivo. Exposure of the basement membrane by micro trauma allows PV to bind to
heparan sulfate proteoglycans (HSPG). Binding of PV to HSPG and subsequent interaction with host cell protein Cyclophilin B causes a conformational change in capsid
structure resulting in the exposure of the N-terminus of L2 (Bienkowska-Haba et al., 2009). L2 has a furin cleavage motif and is cleaved by furin (Richards et al., 2006).
Subsequently, virions are internalized into the basal cells to deliver the viral genome to their nucleus (Day et al., 2013) (A). Clustal analysis of the furin cleavage motif,
R-x-K/R-R (boxed in black) on a variety of HPV and other commonly studied animal PV L2 (B). Clustal analysis was performed with the UCSF Chimera package.
J.W. Wang, R.B.S. Roden / Virology 445 (2013) 175–186 179buried region of L2 that can bind a currently undeﬁned epithelial
cell surface entry receptor, and that it is this L2-receptor interaction
facilitates viral entry along the true infectious pathway. Studies
have suggested two candidate sites on L2 for binding to a putative
entry receptor; one coincident with the RG-1 epitope (13–31), and
another at a region on the surface exposed region of L2 (108–120)
that is recognized by another neutralizing antibody (Kawana et al.,
2001b; Yang et al., 2003a). The 13–31 region binds to cell surfaces
and contains several residues critical for infection by HPV16 (Yang
et al., 2003a), notably the previously mentioned two cysteines
residues that are completely conserved (Campos and Ozbun,
2009; Gambhira et al., 2009). The L2 108–126 region, which
contains a neutralizing epitope, can also bind to epithelial cells
and exhibits sequence conservation (Kawana et al., 1998, 1999).
Interestingly, pre-incubation of 108–126 L2 peptide with cultured
cells reduced PsV infection by 60% compared to control peptides
(Woodham et al., 2012). Further, annexin A2 heterotetramers (A2t)
on epithelial cell surfaces were recently found to interact with this
region and they were proposed as a putative candidate for L2-
receptor binding (Woodham et al., 2012). In summary, furin
cleavage of L2 is both a critical and universal event in PV infection
and it presumably renders L2 able to perform other roles further
downstream of the infectious process. Whether L2 is involved in the
initial uptake (i.e. binding to the secondary receptor) remains a
controversial topic and is an active area of both debate and PV
research.
L2 and vesicular trafﬁcking of papillomavirus
For successful infection, PV needs to enter the host cell, cross
the cytoplasm and transport the viral genome to the nucleus. With
respect to entry, this is actually a two-step process involving viral
entry and subsequently, viral movement into the appropriate
organelles. PV apparently can utilize several different cellular
pathways for internalization, although one particular pathwaymight be dominant and the virus is then able to exploit alternative
pathways should the typical pathway be blocked. It should be
noted that the typical entry route may vary between the cell line/
type and the particular PV genotype studied (see Horvath et al.
(2010) and Sapp and Bienkowska-Haba (2009) for a review). As
mentioned earlier, there has been no discernable difference in
uptake mechanisms in epithelial cells with respect to L1-VLPs and
L1/L2-VLPs with current imaging techniques. However, subtle
differences were noted when studying PV uptake using immune
cells. For example, L1-VLPs enter cells via either clathrin-mediated
or caveolae-dependent mechanisms (Bousarghin et al., 2005; Yan
et al., 2004), whereas L1/L2 VLPs were taken up by clathrin- and
caveolae-independent mechanisms, suggesting that L2 may
impact the uptake pathway. Interestingly while Langerhans cells
that are exposed to L1 VLPs functionally matured and L1/L2 VLPs
lacked this effect. Fahey et al. (2009) suggest that L2 may play a
role in immune escape by re-routing uptake . However, inclusion
of L2 in VLPs did not impact their activation of bone marrow-
derived dendritic cells (Lenz et al., 2001).
In the case of infection of epithelial cells, regardless of the
mode of internalization, consistent ﬁndings suggest that following
cell entry, papillomavirus enters the early endosome and transi-
tions to the late endosome in an acidiﬁcation-dependent process.
Interestingly, the virions have recently been found to pass via the
trans-golgi network, wherein L1 is retained. Entry to the golgi
required furin cleavage of L2, and golgi trafﬁcking mediated by Rab
9a and Rab7b (Day et al., 2013). Other organelles have also been
implicated in the trafﬁcking process, notably caveosomes and the
endoplasmic reticulum for BPV1, HPV31 and HPV16 (Bossis et al.,
2005; Dabydeen and Meneses, 2009; Laniosz et al., 2009, 2008,
2007a). Virions that gain entry to the cytoplasm by an unknown
and possibly L2-dependent mechanism have also been visualized
by transmission electron microscopy, but L1 does not make it to
the nucleus (Ishii et al., 2010; Yang et al., 2003a). Numerous host
cell proteins have also been identiﬁed as interacting partners with
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various mechanisms to the nucleus. These details will be discussed
in the next few sections.
The ﬁrst example is the chaperon protein cyclophilin B (CyPB).
Cyclophilins are peptidyl-prolyl cis/trans isomerases, and it has
been shown in other viruses such as HIV whereby CyPA binds via
the HIV capsid protein motif 85-PXXXGPXXP-93, which is a similar
proline motif those of to L1 interacting motif on L2 (Bienkowska-
Haba et al., 2009). In a similar fashion, CyPB binds to L2 amino acid
region 90–110 (now termed the CyPB-binding site) and it was
thought initially that CyPB-binding merely facilitates the cell-
surface exposure of L2 N-termini for furin cleavage and aid
subsequent cell internalization (Fig. 3A). The authors of the study
however noted that if CyPB was inhibited, non-infectious HPV16
PsV internalization could still occur. In addition, PsVs with
mutated CyPB motifs could also internalize into the cell indepen-
dently of CyPB but were still sensitive to CyPB inhibitors
(Bienkowska-Haba et al., 2009). This suggests that CyPB plays
two distinct roles in HPV infection. Recently, the second role was
elucidated in a study whereby it was shown that CyPB aids in the
uncoating of HPV capsid in the late endosome. Speciﬁcally, CyPB
causes the dissociation of the viral capsid proteins L1 and L2
complexed with the viral DNA into a separate endoyctic compart-
ments (Bienkowska-Haba et al., 2012).
Another host protein that has been recently found to be
important for virion trafﬁcking is the cytosolic adaptor protein
Sortin Nexin 17 (SNX17). SNX17 is an important player in endo-
somal recycling and can be found in early endosomes and
recycling tubules. Key substrates of SNX17 are typically transmem-
brane cargo proteins with a NPxY motif at their cytosolic tails.
Interestingly, studies by the Banks group showed that numerous
PV types have a highly conserved NPxY motif at around amino acid
region 245–257 of L2 that binds to SNX17. They also showed that
knockdown of SNX17 dramatically reduced HPV PsV infectivity.
Conversely, overexpression of SNX17 increased infectivity in a
dosage-dependent manner. Mutation of the NPxY region reduced
viral infectivity suggesting that there is a critical SNX17–L2
interaction. This interaction may prevent premature lysosomal
degradation of the virus as NPxY mutant virions experience
premature lysosomal degradation and the L2-vDNA complex does
not escape the endosome to travel to the nucleus (Bergant and
Banks, 2013; Bergant Marusic et al., 2012).
Lastly, another possible candidate put forward as aiding in PV
transport is the tSNARE syntaxin 18 protein (Bossis et al., 2005;
Laniosz et al., 2007b). Syntaxin 18 binds to L2, and L2 residues
41–45 are critical for this interaction. Mutation of L2 41–45 in theFig. 4. The putative transmembrane domain of L2. Clustal analysis of the transmembran
domains with the colors indicating the conserved GXXXG domains on each face (B) (Bro
(University of Arizona) and American Society for Microbiology. Clustal analysis was percontext of BPV1 eliminated infectivity without compromising encap-
sidation (Bossis et al., 2005). Syntaxin 18 is an ER resident protein
and overexpression of a dominant negative inhibitor blocked both
ER trafﬁcking and BPV1 PsV infection. This suggests a distinct route
of trafﬁcking for BPV1.
L2 and vesicular escape during infection
Following virion dissociation, the viral DNA (vDNA) must escape
the vesicular compartment to be able to travel to the host cell
nucleus. Studies using labeled PsV genome and L2 antibodies have
suggested that L2 in complex with HPV vDNA somehow exits the late
endosome to carry out this process. The information on the mechan-
ism of HPV endosomal escape is an area of active investigation.
Kamper et al. showed that HPV33 L2 C-terminus has a 23 amino acid
region that contains adjacent hydrophobic and basic clusters of
amino acids. The authors showed that full length L2 with this region
or this region fused to GFP was able to integrate into cellular
membranes. The deletion or mutation of this region also abrogated
viral infectivity and consequently the viral genome together with L2
was retained in the late endosome suggesting that this region could
potentially act as a membrane destabilizing peptide for L2/vDNA
endosomal escape (Kamper et al., 2006).
Bronnimann et al. recently described another region in L2 that
potentially could also aid endosome escape. They found that L2
has a transmembrane-like domain region at its N-terminus span-
ning residues 45–67, that includes several highly conserved GxxxG
motifs (Fig. 4). Mutagenesis of some of these GxxxG motifs
resulted in endosomal retention of L2 suggesting the importance
of this region in infection. The authors also noted that the
predicted structure of this domain is alpha-helical in lipid envir-
onments and that these motifs lie on two opposite faces of this
helix (Fig. 4B). Interestingly, based upon some in vitro studies,
these faces could self-associate within biological membranes using
the GxxxG motif. Furthermore, they provide evidence that multi-
ple L2 molecules can associate either homo- or heterotypically via
these GxxxG motifs to potentially form a higher order structure
that could synergistically facilitate endosomal penetration
(Bronnimann et al., 2013).
These ﬁndings do not rule out other host cell protein interac-
tions with this TM domain that could aid endosome escape. Indeed,
we have recently shown that gamma-secretase (GS) is required for
PV infection. Interestingly, GS inhibitors prevent HPV16 PsV infec-
tion and result in retention of L2/genome complex in the late
endosome (Karanam et al., 2010). This suggests that GS facilitates
egress from the late endosome, an L2-depdenent process, but itse-like (TM-like) domain in L2 of fourteen PVs (A). Alpha-helical modeling of the TM
nnimann et al., 2013). Images were reproduced with permission of Samuel Campos
formed with the UCSF Chimera package.
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their transmembrane domain and the above-mentioned studies
suggest that L2 has such a domain indicating a possible interaction.
Indeed substrates of GS are also typically cut with a proprotein
convertase at a position less than 30 residues from the transmem-
brane domain. Interestingly, L2 is cleaved by the proprotein con-
vertase furin at approximately amino acid region 9–12 which is ∼30
residues from the putative transmembrane domain. As mentioned,
inhibition of furin and GS cleavage both result in endosomal
retention of L2 and the viral genome, suggesting these processes
may be functionally related.
L2 and the cytoskeleton
Upon endosome escape, the L2/vDNA complex may utilize the
cytoskeleton to traverse the cytoplasm. L2 is able to interact with
beta-actin at a conserved site found at residues 25–45 (Yang et al.,
2003b), but the locomotive mechanism involving beta-actin was
not deﬁned. Florin et al. describe the binding of L2 with dynein
motors via its C-terminal 40 amino acids. The authors demon-
strated via immunoﬂuorescence and co-immunoprecipitation that
L2 via binding to the motor protein dynein could interact with the
actin microtubule network and conduct minus-end-directed trans-
port of L2/vDNA to the nucleus (Florin et al., 2006). In a subse-
quent study, the same authors further substantiated this using a
combination of two-hybrid assays and immunoﬂuorescence to
reveal DYNLT1 and DYNLT3 (Dynein light chain 1 and 3) as the
main components that work with L2 for microtubule transport
(Schneider et al., 2011).
Nuclear entry by L2
Multiple possible interacting partners of L2 have now been
identiﬁed as aiding traversal of the cytoplasm and vesicular
trafﬁcking. Importantly the mechanism of nuclear entry by L2
differs by stage of the virus life cycle, i.e. viral entry into the
nucleus during the establishment of initial infection versus during
virion production. With respect to the former, it is well established
that L2 is required to go to the nucleus with the vDNA to enact
initial infection (Day et al., 1998; Kondo et al., 2009). Initially, it
was assumed that the L2-vDNA complex entered the nucleus via
nuclear pore complexes via the previously mentioned NLS on both
the N and C-termini of L2. However, the N-terminus NLS is located
upstream of the furin cleavage site and thus might not be present
after entering the cell during infection. Similarly, the C-terminus
NLS is near the membrane destabilizing peptide and may also be a
DNA-binding domain, potentially blocking this NLS. In light of this,
Pyeon et al. showed in a surprising study that the L2-genome
complex enters the nucleus, not via the nuclear pores during
interphase, but rather requires entry to mitosis associated with the
breakdown of the nuclear envelope (Pyeon et al., 2009). Mamoor
et al. also described an arginine-rich nuclear retention signal in L2
has been described in HPV16 L2, comprising residues 296-
SRRTGIRYSRIGNKQTLRTRS-316 that is required for infection but
not virion assembly. It is possible that this region allows for the
association of L2 and the genome complex with the nuclear matrix
during metaphase. In the same study, a leucine-rich nuclear export
signal (NES) was also described at the C-terminus of HPV16 L2,
encompassing residues from 462-LPYFFSDVSL-471. This leucine-
rich region on L2 along with some deletion mutants of the same
region was subsequently fused to GFP and was found to exert
nuclear export in a CRM1 (Exportin)-dependent manner. At pre-
sent, the role of this NES is not clear but it does not appear to be
critical for either pseudovirion assembly or infection (Mamoor
et al., 2012).While the roles of the nuclear localization signals (NLS) at both
its N- and C-termini are unclear with respect to initiation of
infection, these regions can independently interact with karyo-
pherins, speciﬁcally kapα2β1, kapβ2 and kapβ3, for entry into the
nucleus via the nuclear pore complex after the initial ribosomal
synthesis of L2. It is interesting to note BPV1 L2 interacts with
kapα2β1 only which suggests that the nuclear import pathways
are different for different PV types (Bordeaux et al., 2006; Darshan
et al., 2004; Klucevsek et al., 2006; Sun et al., 1995). Heat shock
cognate protein 70 (Hsc70) can also assist in transporting newly
synthesized L2 back into the nucleus via forming an active
complex with L2. Hsc70 is necessary for L2 transport to the
nucleus as depletion of Hsc70 resulted in L2 accumulation in the
cytoplasm. Apart from nuclear transport and entry, Hsc70 may
facilitate viral assembly possibly by maintaining L2 in a speciﬁc
state of folding that is optimal for interaction with the L1-
capsomers. This role was proposed upon ﬁnding that Hsc70 could
be co-sedimented with L1/L2-VLPs but not L1-VLPs suggesting that
Hsc70 is associated with L2 upon its integration into VLPs. Hsc70
could not be detected with PsV suggesting that it can be elimi-
nated by an undeﬁned mechanism during the process of DNA
encapsidation (Florin et al., 2004, 2002a).
Nuclear activities of L2
There is a motif around amino acid region 390–420 that targets L2
to the ND-10 subdomains of the nucleus (also known as PML-
oncogenic domain/POD/PML bodies and deﬁned by co-localization
with PML) (Becker et al., 2004, 2003; Day et al., 1998; Florin et al.,
2002a, 2002b). HPV E1 and E2 can also associate with ND-10
domains during viral DNA synthesis (Swindle et al., 1999). Taken
together, it was proposed that L2 may recruit other PV viral
components to this area possibly to facilitate structural assembly
and/or vegetative replication of the PV genome (Day et al., 2004,
1998; Heino et al., 2000; Schafer et al., 2002). Whereas BPV1 L1, E1
and E2 exhibit diffuse nuclear staining when produced individually
using recombinant Semliki Forest Virus vectors, both BPV and HPV L2
when overexpressed would cause both L1 and E2, but not E1, to co-
localize in a speciﬁc nuclear region known as the ND-10 domain (Day
et al., 1998). Given the importance of L2 in assembly of BPV virions
(and to a smaller extent HPV virions), these ﬁndings suggested that
L2 might act to organize/co-localize the virion components adjacent
to ND-10. However, Buck et al., (2004) found no requirement for E1
or E2 in the assembly of HPV pseudovirions , although this produc-
tion system may not fully mimic vegetative replication and virion
assembly occurring in differentiated epithelium.
It has also been suggested that ND-10 localization is actually
non-physiological and that the L2 accumulation observed is due to
the overexpression system and/or misfolding (Kieback and Muller,
2006). However, Day et al. (2004) also observed that establish-
ment of a papillomavirus infection and viral transcription is
reduced 10-fold in the absence of PML protein (a critical structural
component of ND-10), and that upon infection L2 trafﬁcs to ND-10
in association with the viral genome (Day et al., 2004). These
ﬁndings once again point to the importance of the ND-10 localiza-
tion of L2. However, here it is proposed that the organization of
viral components at ND-10 by L2 may facilitate the early burst of
transcription and replication events at the initiation of infection.
Studies with HPV PsV also show that they bring their encapsi-
dated reporter DNA vectors to ND-10 and efﬁciently initiate
reporter gene expression and vector replication via SV40 T antigen
at low MOIs. While this implies that the interaction between L2
and the encapsidated DNA is not sequence speciﬁc, and initiation
of infection does not require direct interaction between L2 and E2,
it does not rule out a role for L2–E2 interactions in the initiation of
infection by authentic PV virions. Indeed, several studies suggest
Table 1
Published HPV16 L2-speciﬁc neutralizing and cross-neutralizing antibodies.
Monoclonal
antibody
designation
Epitope region
in HPV16 L2
Cross-
neutralizing
ability
Isotype References
RG-1 17–36 Yes IgG2aκ Gambhira
et al.
(2007b)
WW1 17–36 Yes IgG1 Wu et al.
(2011)
MAb24B 58–64 Yes IgG2b Nakao et al.
(2012)MAb13B 64–73 Yes IgG1
K4L220–38 21–30 Yes IgG2b Rubio et al.
(2011)K18L220–38 22–30 Yes IgG1
K8L228–42 32–39 16 only IgG1
K1L264–81 73–79 16 only IgG1
MAb5/Mab13 108–120 Yes IgG2a/3 Kawana
et al. (1999)MAb6 65–81 ?
16L2.4B4 108–120 Yes Undeﬁned Woodham
et al. (2012)
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terminal residues 1–50 of L2 are responsible for binding to E2.
However, L2 residues 301–400 are also required for the down-
regulation of E2-dependent transcriptional activation. L2 does not
reduce transcriptional activation by either lowering E2 protein
levels via reduction of mRNA levels or by enhancing its proteaso-
mal degradation (Okoye et al., 2005). Heino et al. also found that
L2 inhibits the transcriptional activation function of E2 transcrip-
tional transactivator (E2TA), but not its capacity to support viral
DNA replication. Interesting, L2 can bind to and bring the E2-TR
transcriptional repressor form to ND-10, as it binds to two separate
domains of E2 (Heino et al., 2000). Taken together, these ﬁndings
indicate a possible role for L2 in early viral transcription as
infection is initiated.
L2 also causes changes in the ND-10 environment; overexpres-
sion of HPV33 L2 induces the recruitment of Daxx, a nuclear
transcriptional repressor protein that represses transcriptional
activators, to ND-10. The interaction of Daxx with L2 was further
conﬁrmed via co-immunoprecipitation with L2. Furthermore,
overexpression of L2 results in the expulsion from ND-10 and
subsequent degradation of the transcriptional activator, SP100.
Interestingly, proteasome inhibitors prevent the accumulation of
L2 in the nucleus under these conditions and the accumulation of
L1 at ND-10 with L2 only occurred after the exit of SP100. This
adds to the speculation that the accumulation of L2 and Daxx
followed by the loss of SP100 potentially could result in a major
reorganization of the ND-10 environment to facilitate the assem-
bly of virions (Becker et al., 2003; Florin et al., 2002b). The domain
of HPV33 L2 (390–420) that was required for ND-10 localization,
was also required for the loss of SP100 and accumulation of Daxx.
It was also suggested that interaction with Daxx may be also be
the driving force for the localization of L2 into ND-10(Becker et al.,
2003; Florin et al., 2002b). However, it is important to recognize
the caveat that these data were derived using an overexpression
system (Becker et al., 2004; Kieback and Muller, 2006).
Given L2's interaction with E2 and inhibition of E2-dependent
transcriptional activity, it seems plausible that L2 has a role also in
transcriptional regulation. Indeed, a number of relevant L2-
interacting partners have been identiﬁed using yeast 2-hybrid
approaches. Gornemann et al. detected four nuclear body-
associated proteins that could interact with the L2 of different HPV
types and co-localize in the ND-10 domains in some cases. PATZ is a
transcription factor which was found to co-localize in discreteFig. 5. Strong sequence conservation of 17–36aa region (recognized by the RG-1 neut
(C22 and C28) in this region are important for infection and recognition by RG-1 (Campo
the UCSF Chimera package.subnuclear domains and to bind with L2. Interestingly, PATZ is a
zinc ﬁnger family transcriptional regulator and it was postulated that
L2-PATZ interactions might play a role in gene regulation and cell
differentiation during papilloma formation. Other interesting poten-
tial interactions were identiﬁed, including TIP60, TIN-Ag-RP and
PLINP. However, all these identiﬁed interactions require further study
to understand their function (Gornemann et al., 2002). In a more
recent study using the 2-hybrid approach again, the transcription
factors TBX2 and 3 were identiﬁed as interacting partners of L2 at its
c-terminus using HPV11, 16 and 18. The study also found both TBX2
and TBX3 repress viral transcription from the viral LCR of several HPV
types and this repression was enhanced when L2 was overexpressed.
In particular, the levels of early genes such as E6 and E7 were
reduced in HeLa cells when TBX2 was increased. Interaction of TBX2
with the LCR was conﬁrmed by ChIP analysis, and L2 seems to be a
key player in stabilizing this interaction. TBX2/3 co-localization with
L2 can also occur either in the ND-10 domains or throughout the
nuclei depending on the distribution of L2. It is important to
recognize that L2 is usually diffused throughout the nucleus in the
upper stratiﬁed layers of CIN1/2 lesions (Lin et al., 2009), and it is
possible that L2-TBX2/3 interactions here serve to inhibit early viral
gene expression and aid the transition to viral assembly during
infection (Schneider et al., 2013).ralizing antibody) among different HPV types. Note the two cysteine residues
s and Ozbun, 2009; Gambhira et al., 2009). Clustal analysis was performed with
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Two L1 VLP vaccines (GlaxoSmithKline's Cervarixs and Merck's
Gardasils) have been approved by the FDA for the prevention of
HPV-associated cervical neoplasia. Cervarixs contains HPV16 and
18 L1 VLPs, whereas Gardasil is a mixture of these two types as
well as L1 VLPs of low risk types HPV6 and 11 that cause genital
warts. While both vaccines showed high efﬁcacy in preventing
HPV infection in many human clinical trials (Dillner et al., 2010;
Kaufmann and Nitschmann, 2010; Kreimer et al., 2011; Lehtinen
et al., 2012; Romanowski et al., 2009), the protection these
vaccines confer is type-restricted. Given this limitation, second
generation HPV vaccines are being developed. Indeed, Merck is
currently testing a nonavalent L1-VLP HPV vaccine targeting 7 high
risk HPV types to broaden protection among the types most
commonly detected in cervical cancer. However, complex formu-
lation is expensive which could drive up costs and thus indirectlyTable 2
Published list of known protein interactions with PV L2.
Stage of PV
virus life cycle
Protein that
interacts with
L2
Interacting
region on L2
Does the prot
recognize a sp
motif/consens
sequence on L
Prior to infectious cell
entry
Furin 9–12 R-X-K/R-R
Cyclophilin B
(CyPB)
90–110 N/A
Annexin A2
Heterotetramer
108–120 Neutralizing ep
region 108–120
Vesicular trafﬁcking
and endosome
escape
Cyclophilin B
(CyPB)
90–110 N/A
Gamma-
secretase (GS)
Unknown Unknown
Sortin Nexin
17 (SNX17)
245–257 F/YxNPxF/Y
Nuclear transport Syntaxin 18
(BPV1 only)
43–47 DQ/KILQ/K
Heat shock
cognate
protein 70
(Hsc70)
Unknown N/A
Beta-actin 25–45 N/A
Dynein motor
proteins
(DYNLT1 & 3)
456–460, 457–461
(HPV16 L2)
R/KR/KXXR/K
Karyopherins
(Kapβ2 and
Kapβ3)
1–9 or 454–462 (NLS
signals at the amino and
carboxyl termini
respectively)
N/A
Viral gene regulation,
morphogenesis and
assembly
ND-10 domain
and binding to
Daxx
390–420 N/A
PV E2 1–50 and 301–400 N/A
PV L1 412–455 PXXP
TBX2 and
TBX3
L2 C-terminus region N/A
Other known
interaction protein
partners but with
undeﬁned function
 PATZ
 TIP60
 TIN-AG-RP
 PLINP
Unknown Unknown
SUMO (small
ubiquitin-
related
modiﬁers)
34–37 PVKEdiscourage vaccine usage in low resource settings where a broadly
protective HPV vaccine is most needed (Schiller and Lowy, 2012).
Alternatively, the HPV minor capsid protein L2 is an interesting
candidate that may address the aforementioned requirements of cost
and broad coverage. L2 can be expressed as a single antigen in bacteria
and this could potentially bring down production costs. More sig-
niﬁcantly, vaccination studies with L2 in animal challenge models
showed the production of antibodies neutralizing for a wide spectrum
of PV types, and similarly broad protection from experimental viral
challenges (Campo et al., 1997; Embers et al., 2002; Gambhira et al.,
2007a; Jagu et al., 2009; Kawana et al., 2001a, 2001b; Lin et al., 1992).
Passive transfer of L2-speciﬁc neutralizing antibodies is sufﬁcient to
mediate protection of mice from cutaneous or vaginal challenge with
HPV pseudovirions (Day et al., 2010; Gambhira et al., 2007a, 2007b;
Jagu et al., 2013). While some variation in these neutralizing epitopes
is apparent (Seitz et al., 2013), sequence comparison at the N-terminus
of L2 reveals high conservation across PV types (Fig. 5), includingein
eciﬁc
us
2?
Purpose of
interaction
References
Cleavage of L2 Richards et al. (2006)
Assist in capsid conformational
change for secondary receptor
uptake
Bienkowska-Haba et al. (2009)
itope Putative secondary receptor Woodham et al., (2012)
Assist in capsid disassembly
in the late endosome
Bienkowska-Haba et al. (2012)
Facilitates L2/vDNA
endosomal escape
Karanam et al. (2009)
Bergant Marusic et al. (2012)
Bergant and Banks (2013)
Transport of L2 toward nucleus Bossis et al. (2005)
Laniosz et al., (2007a)
Florin et al. (2004)
Yang et al. (2003b)
Florin et al. (2006)
Schneider et al. (2011)
Bordeux et al. (2006), Darshan
et al. (2004), Klucevsek et al.
(2006), Fay et al., (2004), Sun et al.
(1995)
Recruits other viral proteins and
viral DNA to initiate viral gene
transcription or assembly?
Becker et al. (2003)
Florin et al. (2002b)
L2 brings E2 to the ND-10
domains (possibly to initiate
viral gene transcription or
replication)
Okoye et al. (2005)
Heino et al. (2000)
Viral capsid assembly Finnen et al. (2003)
Lowe et al. (2008)
L2 brings TBX2/3 to the viral
genome's LCR where TBX2/3
then represses of viral gene
transcription
Schneider et al. (2013)
Unknown Gornemann et al. (2002)
Unknown Marusic et al. (2010)
J.W. Wang, R.B.S. Roden / Virology 445 (2013) 175–186184regions that are recognized by neutralizing monoclonal antibodies
(Fig. 1 and Table 1) (Christensen et al., 1991; Rubio et al., 2011).
The reason for sequence conservation in these L2 epitopes which is
potentially detrimental to the virus has been debated. Several expla-
nations have been put forward as to why the neutralizing epitopes are
conserved in L2, but not L1. Firstly, L2 is hidden in the virus capsid
unlike the surface loops of L1 that form the immunodominant
neutralizing epitopes of VLPs. This could explain the lack of evolu-
tionary pressure for these epitopes drift in sequence (Roden et al.,
2001). Secondly, the conservation of the L2 neutralizing epitopes also
suggests an evolutionary constraint that may reﬂect binding to a
cellular entry factor or some other critical role during infection
(Kawana et al., 2001b; Woodham et al., 2012; Yang et al., 2003a).
Unfortunately, L2 provided no discernable beneﬁt in the con-
text of L1/L2 VLPs (Breitburd et al., 1995; Kirnbauer et al., 1996),
and the immune response produced to vaccination with L1/L2
VLPs was found to be predominantly an anti-L1 response (Roden
et al., 2000). This skewed response has not been fully understood
but has been attributed to the overall number of L1 (which have
numerous immunogenic epitopes also) compared to L2 in a single
virus capsid, and distant spacing of L2 compared to L1, and
possibly low occupancy of L2 in L1/L2 VLPs. Further, L2 is buried
in the PV capsid and thus possibly hidden from or only exposed
transiently to B cells. The challenge ahead for L2-based vaccines is
to ﬁnd methods to expose L2 to the immune system to induce and
maintain protective levels of antibodies to these L2 epitopes for
many decades. Many methods have been utilized with varying
success at the preclinical setting and the reader is directed to
(Karanam et al., 2009; Schiller and Lowy, 2012; Wang and Roden,
2013) for a more comprehensive coverage of this topic.Conclusion
It is clear that L2 has complex and multifunctional roles in the
biology of all PVs, notably in virion assembly and early events of
infection, and has potential as a vaccine antigen. A recurring
theme in our discussion of L2 biology is that while many
functional domains and numerous host-cell protein interacting
partners are now recognized (Table 2), the detailed mechanism
of their action remains controversial or unclear in many cases.
The challenges ahead for PV L2-based research are to obtain an
atomic structure of L2, and to decipher how host proteins that
interact with L2 impact the biology of PV. The PaVE website will be
a valuable tool to collate and disseminate these ﬁndings.Acknowledgments
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